The hypomethylating agents 5-azacytidine and decitabine show efficacy in myeloid neoplasms such as AML, and the response rate to these drugs appears to correlate with TET2, IDH1/2, and/or DNMT3A mutations. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.